Recruiting

EXOMIND & EMSELLA

Sponsor:

BTL Industries Ltd.

Code:

NCT07413705

Conditions

Depressive Symptoms

Urinary Incontinence

Sexual Dysfunction

Eligibility Criteria

Sex: Female

Age: 40+

Healthy Volunteers: Not accepted

Interventions

EXOMIND (BTL-699-2) Active Treatment

EMSELLA (HPM-6000UF) ActiveTreatment

EXOMIND (BTL-699-2) Sham Treatment

EMSELLA (HPM-6000UF) Sham Treatment

Study Details

Brief summary:

The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or postmenopausal without an alternative medical cause before enrollment in the study and are aged 40 years and older. The main question it aims to answer is: Does the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices improve depressive symptoms and urinary incontinence? Participants will be asked to:

Undergo twelve treatments Complete the Patient Health Questionnaire-9 Complete the 6-item Hamilton Depression Rating Scale Complete the Greene Climacteric Scale Complete the Therapy Comfort Questionnaire Complete the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form Complete the Female Sexual Function Index Complete the Warwick-Edinburgh Mental Wellbeing Scale Complete the Columbia Suicide Severity Rating Scale-Screen version Complete the Subject Satisfaction Questionnaire Complete the Therapy Comfort Questionnaire

Conditions

Depressive Symptoms

Urinary Incontinence

Sexual Dysfunction

Study ID

NCT07413705

Start date

Nov 20, 2025

Status verified date

Dec, 2025

Completion date

Dec 11, 2026

Anticipated

Primary completion date

Dec 11, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Menopause defined as 12 consecutive months with no menses without an alternative medical cause or perimenopause defined as occurrence of ≥ 60 days of amenorrhea without an alternative medical cause
  • Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5
  • Age ≥ 40 years
  • Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the finger
  • Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the improvement of depressive symptoms and/or sexual function, including non-invasive brain stimulation treatments other than the study procedure during study participation
  • Willingness to comply with study instructions and to return to the clinic for the required visits
  • Women of childbearing potential\* are required to use birth control measures during the whole duration of the study
  • If applicable, subjects will be maintained on pre-study psychotherapeutic regime, and prescribed chronic medications at a stable therapeutic dosage for at least 1 month prior to study entry \*defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.

Exclusion Criteria:

  • Metallic objects in or near the head
  • rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil\*
  • Implanted stimulator devices, implanted defibrillators, implanted neurostimulators
  • Cardiac pacemakers
  • Electronic implants
  • Metal implants
  • rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. - Contraindicated use could result in serious injury or death.
  • Drug pumps
  • Application in the heart area
  • Application of HPM-6000UF in the head area
  • Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy)
  • Anticoagulation therapy
  • Severe or life-threatening condition
  • Pulmonary insufficiency
  • Heart disorders
  • Renal insufficiency
  • Decompensated\*\* hemorrhagic conditions
  • Decompensated\*\* blood coagulation disorders
  • Decompensated\*\* cardiovascular diseases
  • Malignant tumor or benign tumor
  • Fever
  • Pregnancy

Study specific:

  • Active suicidal intent
  • History of suicide attempts in the last 3 years
  • History or concurrent use of electroconvulsive therapy or vagus nerve stimulation
  • Substance-induced depression or depression secondary to a general medical condition
  • Diagnosis of seasonal affective disorder, psychotic disorder including schizoaffective disorder or current psychotic symptoms, major depression with psychotic features, bipolar disorder
  • Substance abuse
  • Dependence 3 months prior
  • Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders
  • History of increased intracranial pressure or head trauma
  • Nursing
  • Ongoing intake disorders such as bulimia or anorexia, or intake disorder in the past 12 months
  • Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study

  • Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. - Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered.

  • By means of decompensation, it means a patient with a proven medical history of the decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Active treatment with BTL-699-2 and HPM-6000UF

Participants will receive active treatment (BTL-699-2 intensity: up to 70% of MT, HPM-6000UF intensity: up to 100%)

sham comparator: Sham treatment with BTL-699-2 and HPM-6000UF

Participants will receive sham treatment (BTL-699-2 intensity: 1% of MT, HPM-6000UF intensity: 1%)

Interventions

EXOMIND (BTL-699-2) Active Treatment

Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.

EMSELLA (HPM-6000UF) ActiveTreatment

Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be adjusted according to the subject's feedback, up to 100%. The treatments will be spaced 3 - 7 days apart.

EXOMIND (BTL-699-2) Sham Treatment

Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be set to 1% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.

EMSELLA (HPM-6000UF) Sham Treatment

Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be set to 1%. The treatments will be spaced 3 - 7 days apart.

Primary outcome measure

  • Assessment of Change in Subjective Depressive Symptoms in Perimenopausal and Postmenopausal Women [ Time Frame: 15 months ]

Central Contacts and Locations

Locations

Luxury Psychiatry Clinic

Recruiting

Winter Garden, Florida, United States, 34787

Contacts

Michelle Dees, MD

(407) 603-0925michelledees@hotmail.com

Aesthetic + Mind MD

Recruiting

Wellesley, Massachusetts, United States, 02481

Contacts

Omotola Tsarumi, MD

(617) 668-1239info@drtola.com

Vitality MD Inc

Recruiting

Toronto, Ontario, Canada, M5M3Y8

Contacts

Shari Caplan, MD, CCFP, FCFP, ABOIM

(416) 792-1100sharicaplan@me.com

More Information

Sponsor

BTL Industries Ltd.

Last update posted

Feb 17, 2026

Last verified

Dec, 2025

Keywords

  • Depressive Symptoms
  • Depression
  • Urinary Incontinence
  • Sexual Dysfunction
  • Sexual Function
  • ExoTMS
  • Perimenopause
  • Postmenopause
  • EMSELLA
  • EXOMIND

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by BTL Industries Ltd. on 2026-02-17.